読み込み中
HKSEHealthcareBiotechnology
最新データ
HK$3.80
−HK$0.20 · -5.00%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
最新データ
HK$3.80
−HK$0.20 · -5.00%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52週レンジ
現在 HK$3.80
過去の価格は調整または遅延している場合があります。
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52週レンジ
現在 HK$3.80
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（HKD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3711.77万 HKD | 7791.83万 HKD | 7375.18万 HKD | 3737.91万 HKD | 1.07億 HKD |
| 売上原価 | 290.02万 HKD | 1047.12万 HKD | 2192.58万 HKD | 1018.19万 HKD | 626.39万 HKD |
| 粗利益 | 3365.16万 HKD | 6674.84万 HKD | 5182.6万 HKD | 2719.73万 HKD | 1億 HKD |
| 研究開発 | 9232.98万 HKD | 1.24億 HKD | 1.4億 HKD | 7012.06万 HKD | 1.4億 HKD |
| 販売・一般管理 | 4253.98万 HKD | 4450.23万 HKD | 1.54億 HKD | 1.16億 HKD | 3.28億 HKD |
| 営業費用 | 1.84億 HKD | 2.18億 HKD | 2.93億 HKD | 2.55億 HKD | 5.12億 HKD |
| 受取利息 | 510.09万 HKD | 516.89万 HKD | 1454.12万 HKD | 380.51万 HKD | — |
| 支払利息 | 10.28万 HKD | 11.92万 HKD | 6.31万 HKD | 8.09万 HKD | — |
| 減価償却費と償却費 | 1161.7万 HKD | 1053.6万 HKD | 1175.65万 HKD | 1196.09万 HKD | 1065.53万 HKD |
| 営業利益 | −1.51億 HKD | −1.84億 HKD | −2.41億 HKD | −2.28億 HKD | −4.11億 HKD |
| 純利益 | −1.43億 HKD | −1.56億 HKD | −2.1億 HKD | −1.83億 HKD | −4.18億 HKD |
会社概要が更新されました 2026年10月17日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
